Leigh  Zawel net worth and biography

Leigh Zawel Biography and Net Worth

Insider of Cullinan Oncology
Leigh Zawel is Chief Scientific Officer, Small Molecules at Cullinan and an Executive Partner at MPM Capital.

Prior to joining Cullinan and MPM, Leigh led Pfizer’s Center for Therapeutic Innovation and worked as the site head for Pfizer’s New York and Boston offices. Prior to Pfizer, Leigh was the oncology site lead at Merck Research Laboratories Boston, where he was responsible for drug discovery efforts focused on the identification of development candidates for programs in the oncology franchise. Leigh worked previously at Sanofi-Aventis, where he was Director of Cancer Biology, and Novartis Institutes for Biomedical Research/Oncology, where he was an Oncology Group Leader. Leigh has a deep background in identifying and validating oncology drug targets and in transitioning drug discovery programs through lead optimization to Phase 1 clinical trials.

Leigh earned his Ph.D. in the laboratory of Danny Reinberg where he identified and characterized components of the RNA Polymerase II basal transcription machinery. Leigh’s postdoctoral training was in the laboratory of Bert Vogelstein and Ken Kinzler and focused on dysregulation of TGFB signaling in cancer. Leigh also holds an M.S. in Bacteriology from the University of Wisconsin, as well as a B.S. in Biology from Rutgers University. He has published more than 30 scientific publications. He is also an author on 45 patents covering chemical matter, drug combinations, biomarker utility, and gene function in areas of apoptosis, inflammation and TGFB signaling.

How do I contact Leigh Zawel?

The corporate mailing address for Mr. Zawel and other Cullinan Oncology executives is , , . Cullinan Oncology can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Leigh Zawel's contact information.

Has Leigh Zawel been buying or selling shares of Cullinan Oncology?

Leigh Zawel has not been actively trading shares of Cullinan Oncology in the last ninety days. Most recently, Leigh Zawel sold 19,574 shares of the business's stock in a transaction on Friday, October 15th. The shares were sold at an average price of $25.00, for a transaction totalling $489,350.00. Learn More on Leigh Zawel's trading history.

Who are Cullinan Oncology's active insiders?

Cullinan Oncology's insider roster includes Nadim Ahmed (Pres), Ansbert Gadicke (Director), Jennifer Michaelson (Insider), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Oncology's active insiders.

Are insiders buying or selling shares of Cullinan Oncology?

During the last twelve months, insiders at the sold shares 26 times. They sold a total of 128,339 shares worth more than $1,748,747.70. The most recent insider tranaction occured on February, 1st when insider Corrine Savill sold 40,000 shares worth more than $647,200.00. Insiders at Cullinan Oncology own 8.8% of the company. Learn More about insider trades at Cullinan Oncology.

Information on this page was last updated on 2/1/2024.

Leigh Zawel Insider Trading History at Cullinan Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/15/2021Sell19,574$25.00$489,350.00View SEC Filing Icon  
10/7/2021Sell1,079$25.00$26,975.00View SEC Filing Icon  
9/7/2021Sell28,118$28.95$814,016.10View SEC Filing Icon  
8/9/2021Sell21,204$26.57$563,390.28View SEC Filing Icon  
See Full Table

Leigh Zawel Buying and Selling Activity at Cullinan Oncology

This chart shows Leigh Zawel's buying and selling at Cullinan Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cullinan Oncology Company Overview

Cullinan Oncology logo
Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $17.04
Low: $17.02
High: $17.79

50 Day Range

MA: $16.68
Low: $11.51
High: $19.02

2 Week Range

Now: $17.04
Low: $7.64
High: $19.68

Volume

394,192 shs

Average Volume

429,467 shs

Market Capitalization

$733.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34